High LDL cholesterol rarely causes symptoms, so most people learn about it from a blood test. About 25% of US adults have an LDL level of 130 mg/dL or higher, raising heart attack and stroke risk, while new-patient family medicine waits average 23.5 days across 15 large US metros (AMN Healthcare, 2025).

Ask a direct question: do you want a service with ongoing subscriptions and tied medication bundles, or a doctor of your own? If you want what another company sells beyond the doctor, or an in-person exam, those are strong options. Otherwise, FutureClinic gives you an expert physician with nothing attached.

Every FutureClinic doctor is a licensed physician with an MD, DO or MBBS degree, never a nurse practitioner or physician assistant. No form is approved in bulk: a specific doctor reads your case and replies with your plan and a Human Signature, a short video or voice note recorded live for you. You can message the same doctor time after time, however long in between, to compare lipid panels, adjust a dose, or switch medicines. That doctor can also help with other problems in their specialty, and every FutureClinic doctor you see works from one medical record.

How does one-to-one care with the same doctor work?

Your doctor's only incentive is to help you. FutureClinic sells no medicines, and your doctor earns nothing extra for any prescription or test. They never upsell a lab panel or drug, you never have to stay subscribed month after month to keep your medicine, and no house formulary steers them. They can prescribe any appropriate brand or generic medicine to the pharmacy you choose, if your doctor decides it's right for you.

The 2026 ACC/AHA dyslipidemia guideline (March 2026) retired the 2018 rules and stresses earlier care, including considering medicine in young adults with LDL of 160 mg/dL or higher or a strong family history of early heart disease. Inherited high LDL affects 1 in 250 to 300 people (up to 90% undiagnosed). For adults 30 to 79, the AHA PREVENT equations estimate 10-year risk across low (below 3%), borderline (3% to under 5%), intermediate (5% to under 10%), and high (10% or more) tiers using history and lab values shared by message.

We believe AI is a tool for doctors, with the human doctor in charge. Most health problems have nuance needing one-to-one care, and only an expert knows when an AI makes a mistake or heads to the wrong answer. Behind the scenes, FutureClinic's AI works like a chief resident, gathering your history and labs to speed up review, and it never gives medical advice by itself. After you confirm the summary, your doctor decides on your care and replies typically within a few hours, almost always the same day or the next.

What lab tests and targets apply in 2026?

Share recent labs, or have your doctor order lab tests at discounted prices.

• Standard lipid profile: Measures total cholesterol, HDL, and triglycerides, calculating LDL and non-HDL. Per the 2026 guideline, most people need not fast, though NHLBI notes a provider may ask for an 8- to 12-hour fast, and fasting is advised for a family history of lipid disorders or early heart disease, a triglyceride disorder, or nonfasting triglycerides of 400 mg/dL or higher.
• Lipoprotein(a) and apoB: The 2026 guideline recommends measuring lipoprotein(a) at least once without fasting (125 nmol/L or 50 mg/dL enhances risk; 250 nmol/L or 100 mg/dL roughly doubles it). ApoB and hsCRP help refine risk.
• 2026 LDL goals: Below 55 mg/dL (non-HDL below 85 mg/dL) for very high-risk cardiovascular disease; below 70 mg/dL for other cardiovascular disease, high-risk primary prevention, or multi-risk diabetes; and below 100 mg/dL at borderline or intermediate risk on a statin, or for adults 40 to 75 with diabetes.

AI high cholesterol treatment: the medications a doctor can prescribe online

The 2026 guideline recommends plant-forward diets and advises against supplements after a trial showed fish oil, red yeast rice, plant sterols, garlic, cinnamon, and turmeric did not lower LDL versus placebo.

• Statins: First-line therapy. In a 2010 CTT meta-analysis of 26 trials, each 1.0 mmol/L (39 mg/dL) LDL drop cut major vascular events by about 22% and deaths by 10%. Preferred statins are atorvastatin (39% to 60% average LDL drop at 10 to 80 mg in 6-week trials) and rosuvastatin (45% to 63% average drop at 5 to 40 mg). In a 2022 CTT analysis of 19 trials (123,940 people), 27.1% on statins versus 26.6% on placebo reported muscle symptoms, showing over 90% of complaints were not statin-caused. For the roughly 10% who cannot tolerate maximum daily doses, your doctor can switch statins or adjust dosing by message.
• Nonstatins and triglyceride drugs: Daily 10 mg ezetimibe is the first primary-prevention add-on in most cases (18% average LDL drop alone in 12-week trials; about 25% added to a statin). Others include oral bempedoic acid (20% LDL drop at month 6; fewer events in CLEAR Outcomes), self-injected PCSK9 antibodies (Repatha and Praluent, 45% to 64% LDL drop), monthly self-injected Lerochol (December 2025, 50% to 59% trial LDL drop), daily oral Lipfendra (July 2026, 56% to 59% trial LDL drop; both newer drugs labeled for LDL lowering only), and icosapent ethyl for high triglycerides on a statin (17.2% versus 22.0% events on placebo in REDUCE-IT).